Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.92 USD | -1.75% | -7.71% | +37.30% |
Feb. 09 | Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating | MT |
Feb. 07 | Transcript : Enanta Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 07, 2024 |
Financials (USD)
Sales 2024 * | 68.81M | Sales 2025 * | 73.31M | Capitalization | 273M |
---|---|---|---|---|---|
Net income 2024 * | -110M | Net income 2025 * | -116M | EV / Sales 2024 * | 3.97 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3.73 x |
P/E ratio 2024 * |
-2.48
x | P/E ratio 2025 * |
-2.62
x | Employees | 145 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.9% |
Latest transcript on Enanta Pharmaceuticals, Inc.
1 day | -1.75% | ||
1 week | -7.71% | ||
Current month | -26.00% | ||
1 month | -11.45% | ||
3 months | +6.78% | ||
6 months | +43.88% | ||
Current year | +37.30% |
Managers | Title | Age | Since |
---|---|---|---|
Jay Luly
CEO | Chief Executive Officer | 67 | 03-06-30 |
Paul Mellett
DFI | Director of Finance/CFO | 68 | 03-08-31 |
Chief Tech/Sci/R&D Officer | 50 | 22-08-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Foletta
BRD | Director/Board Member | 63 | 20-06-28 |
Lesley Russell
BRD | Director/Board Member | 63 | 16-11-17 |
Bruce Carter
CHM | Chairman | 80 | 13-11-24 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.10% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 12.92 | -1.75% | 90,291 |
24-04-23 | 13.15 | -2.16% | 108,198 |
24-04-22 | 13.44 | +0.90% | 67,129 |
24-04-19 | 13.32 | +0.68% | 139,429 |
24-04-18 | 13.23 | -5.50% | 154,132 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+37.30% | 273M | |
+4.09% | 43.84B | |
+46.23% | 41.25B | |
+9.45% | 41.68B | |
-10.92% | 27.04B | |
+9.32% | 25.53B | |
-24.87% | 18.18B | |
+29.70% | 12.29B | |
+1.28% | 12.29B | |
+7.78% | 11.15B |
- Stock Market
- Equities
- ENTA Stock